BioSight
Companies
SOPHiA GENETICS SA logo

SOPH

NASDAQROLLE, V8
SOPHiA GENETICS SA

SOPHiA GENETICS is a cloud-native software technology company that provides the SOPHiA DDM platform for analyzing multimodal healthcare data including genomic, radiomic, clinical, and biological data across oncology, rare diseases, infectious diseases, cardiology, neurology, and metabolism. The company offers research-use-only and CE-IVD applications including SOPHiA CarePath, a multimodal analytics module, and the Digital Twins tool for simulating patient outcomes, serving over 993 hospital, laboratory, and biopharma customers globally as of December 2025.

Price history not yet available for SOPH.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar